MENU
APR 29, 2021

OncomineWorld 2021: A virtual NGS education meeting


Our OncomineWorld events in 2020 and 2021 brought thousands of professionals together from around the world to advance understanding of next-generation sequencing in precision oncology research. The most recent meeting was held on April 29, 2021. We are pleased to announce that all event content is now available to access on demand!   
 
The 2021 featured content includes presentations and discussions about hot and emerging biomarker testing, such as genomic instability, and new user experiences with the Ion Torrent Genexus NGS System in solid and hematologic tumor clinical research.
 
What can you expect from OncomineWorld 2021?
In addition to earning continuing education (CE) credits from on-demand presentations, you will also have access to all that the OncomineWorld universe has to offer -

  • Demonstrations of the Ion Torrent Genexus System and Genexus Software
  • The latest NGS research from Thermo Fisher Scientific with new posters in the Poster Hall
  • New content in the Precision Oncology Hall, with all about why and how genomic profiling for precision oncology should be done in-house, locally and close to patients
  • Virtual laboratories introducing the new world of easy and fast NGS – the Genexus System - and NGS application areas like emerging NSCLC biomarkers, comprehensive genomic profiling (CGP), liquid biopsy research, and hemato-oncology research.

 


 
For Research Use Only. Not for use in diagnostic procedures.


Speakers
  • Unipath Specialty Laboratory
  • Assistant Professor, Molecular Genetic Pathology and Neuropathology, Co-Director, Molecular Diagnostics Laboratory, University of Texas Health​ Science Center at Houston
  • Professor, University of Auckland
  • President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
  • Associate Director, Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • Professor of Molecular Pathology, University of Munich
  • Head of Department of Molecular Diagnostics, Holycross Cancer Center
  • Scientific Medicial Director of Genetics/Genomics Division at Sonora Quest Laboratories, Associate Professor of Pathology Department at University of Arizona
  • Senior Consultant
  • Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
  • Product Manager, Clinical Sequencing Division, Thermo Fisher Scientific
  • Physician Lead of Research, Medical Director of Immunohistochemistry and Molecular Pathology, Department of Pathology, William Osler Health System
  • Senior Clinical Scientist, Department of Haematology, Royal Liverpool University Hospital

Show Resources
You May Also Like
JUN 08, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 08, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
The global pandemic has not only changed our plans for how we live and work, but also accelerated the need for innovation to protect human health. Join us for an Innovation Summit to hear fi...
JUN 17, 2021 3:00 PM BST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 17, 2021 3:00 PM BST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Each step in a diagnostic test's journey-from raw material extraction to patient administration-can influence outcomes....
JUN 09, 2021 6:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 09, 2021 6:30 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Bioprocess technology implementation is hard. Get ahead by getting it right. How do you know if you’re making the right decisions about bioproduction technologies? There is no universa...
APR 19, 2022 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
APR 19, 2022 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to announce our 10th Annual Genetics Virtual Week held on April 19-21, 2022! Genetics Virtual Week 2022 will offer a multi-day content-rich program combining stellar expe...
NOV 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Twelveyears ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event will again bring together clinician...
NOV 09, 2022 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 09, 2022 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Thirteen years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2022 Clinical Diagnostics and Research Virtual Event will again bring together clinic...
Agenda
  • A clinical-research-industry collaboration to bring blood genomics to cancer patients in New Zealand
    APR 29, 2021 12:05 PM +08
    A clinical-research-industry collaboration to bring blood genomics to cancer patients in New Zealand
    Cristin Gregor Print, PhD
    Professor, University of Auckland
  • Current and upcoming pharma collaboration and IVD strategy
    APR 29, 2021 12:25 PM +08
    Current and upcoming pharma collaboration and IVD strategy
    Garret Hampton
    President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
  • Comprehensive Genomic Profiling, an Asia Pacific Perspective - AsPION Project
    APR 29, 2021 1:15 PM +08
    Comprehensive Genomic Profiling, an Asia Pacific Perspective - AsPION Project
    Dr. Tony Lim
    Senior Consultant
  • Validation of combined DNA and RNA sequencing in Myeloid neoplasms
    APR 29, 2021 1:35 PM +08
    Validation of combined DNA and RNA sequencing in Myeloid neoplasms
    Neeraj Arora, MD, PDF
    Unipath Specialty Laboratory
  • APR 29, 2021 2:10 PM +08
    Genexus System and Genexus Software Demo
    Andrew Hutchison, Uma Ramasubramanian
    Andrew Hutchison
    Associate Director, Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
    Uma Ramasubramanian
    Product Manager, Clinical Sequencing Division, Thermo Fisher Scientific
  • Molecular pathology clinical and research activities in the COVID-19 era
    APR 29, 2021 3:05 PM CEST
    Molecular pathology clinical and research activities in the COVID-19 era
    Nicola Normanno, MD
    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
  • NSCLC molecular profiling: An NGS based approach using Oncomine Solutions
    APR 29, 2021 3:25 PM CEST
    NSCLC molecular profiling: An NGS based approach using Oncomine Solutions
    Artur Kowalik, Ph.D.
    Head of Department of Molecular Diagnostics, Holycross Cancer Center
  • Comprehensive Genomic Profiling for Homologous Recombination Repair Deficiency (HRD) Assessment
    APR 29, 2021 4:15 PM CEST
    Comprehensive Genomic Profiling for Homologous Recombination Repair Deficiency (HRD) Assessment
    Dr. Andreas Jung
    Professor of Molecular Pathology, University of Munich
  • Haematological malignancy samples molecular characterization - in a NGS way
    APR 29, 2021 4:35 PM CEST
    Haematological malignancy samples molecular characterization - in a NGS way
    Lihui Wang, Ph.D.
    Senior Clinical Scientist, Department of Haematology, Royal Liverpool University Hospital
  • APR 29, 2021 5:10 PM CEST
    Genexus System and Genexus Software Demo
    Andrew Hutchison, Uma Ramasubramanian
    Andrew Hutchison
    Associate Director, Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
    Uma Ramasubramanian
    Product Manager, Clinical Sequencing Division, Thermo Fisher Scientific
  • APR 29, 2021 2:10 PM PDT
    Genexus System and Genexus Software Demo
    Andrew Hutchison, Uma Ramasubramanian
    Andrew Hutchison
    Associate Director, Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
    Uma Ramasubramanian
    Product Manager, Clinical Sequencing Division, Thermo Fisher Scientific
  • Experience with the Oncomine Precision Assay on Genexus System
    APR 29, 2021 1:35 PM PDT
    Experience with the Oncomine Precision Assay on Genexus System
    Leomar Ballester, MD, PhD
    Assistant Professor, Molecular Genetic Pathology and Neuropathology, Co-Director, Molecular Diagnostics Laboratory, University of Texas Health​ Science Center at Houston
  • Oncomine Reporter: A Powerful Tool for Oncology NGS Reports
    APR 29, 2021 1:15 PM PDT
    Oncomine Reporter: A Powerful Tool for Oncology NGS Reports
    Xia Li, Ph.D., DABMGG, CG(ASCP), FACMG
    Scientific Medicial Director of Genetics/Genomics Division at Sonora Quest Laboratories, Associate Professor of Pathology Department at University of Arizona
  • Current and upcoming pharma collaboration and IVD strategy
    APR 29, 2021 12:25 PM PDT
    Current and upcoming pharma collaboration and IVD strategy
    Garret Hampton
    President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
  • Point of care NGS in community practice
    APR 29, 2021 12:05 PM PDT
    Point of care NGS in community practice
    Brandon Sheffield, MD, FRCPC
    Physician Lead of Research, Medical Director of Immunohistochemistry and Molecular Pathology, Department of Pathology, William Osler Health System
  • Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
    OCT 22, 2020 1:35 PM PDT
    Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
    Jane Bayani, PhD
    Principal Research Scientist, Ontario Institute for Cancer Research
  • Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
    OCT 22, 2020 1:15 PM PDT
    Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
    Craig Mackinnon, MD, PhD
    Director, Genomic Diagnostics and Bioinformatics - Professor, Department of Pathology, University of Alabama at Birmingham
  • Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
    OCT 22, 2020 12:25 PM PDT
    Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
    Megan S. Lim, MD, PhD
    Director of the Division of Hematopathology, Hospital of the University of Pennsylvania
  • Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
    OCT 22, 2020 12:05 PM PDT
    Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
    Carmen Kletecka, MD, FCAP, FASCP
    Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
  • First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
    OCT 22, 2020 4:40 PM CEST
    First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
    Ines Raineri, MD
    Staff Pathologist, Institute for Pathology medica AG
  • NGS evolution in Solid Tumours, from S5-XL to Genexus
    OCT 22, 2020 4:20 PM CEST
    NGS evolution in Solid Tumours, from S5-XL to Genexus
    Javier Hernandez-Losa, PhD
    Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
  • Next Generation rEvolution in Myeloid Neoplasms clinical research
    OCT 22, 2020 3:35 PM CEST
    Next Generation rEvolution in Myeloid Neoplasms clinical research
    Giada Rotunno, PhD
    Research Scientist, University of Florence
  • NGS for precision oncology in solid tumors: from research to clinical practice
    OCT 22, 2020 3:05 PM CEST
    NGS for precision oncology in solid tumors: from research to clinical practice
    Nicola Normanno, MD
    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
  • Latest Developments with the Genexus System
    OCT 22, 2020 1:35 PM SGT
    Latest Developments with the Genexus System
    Dr. Jose Luis Costa
    Medical Director, Thermo Fisher Scientific
  • OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
    OCT 22, 2020 1:15 PM SGT
    OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
    Ahwon Lee, MD, PhD
    Professor, Catholic University of Korea and Pathologist, Seoul St. Mary's Hospital
  • The role of PARPis and HRD testing in advanced ovarian cancer
    OCT 22, 2020 12:25 PM SGT
    The role of PARPis and HRD testing in advanced ovarian cancer
    Natalie Ngoi, MBBS, MMed, MRCP
    Associate Consultant, National University Cancer Institute, Singapore
  • Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
    OCT 22, 2020 12:05 PM SGT
    Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
    Aaron Tan, PhD
    Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
  • Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
    MAY 14, 2020 7:05 PM EDT
    Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
    Timothy Looney, PhD
    Associate Director, Bioinformatics; Clinical Next-Generation Sequencing
  • Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
    MAY 14, 2020 6:40 PM EDT
    Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
    Jane Bayani, PhD
    Principal Research Scientist, Ontario Institute for Cancer Research
  • Experience with Oncomine Myeloid Research Assay
    MAY 14, 2020 6:05 PM EDT
    Experience with Oncomine Myeloid Research Assay
    Xia Li, Ph.D., DABMGG, CG(ASCP), FACMG
    Scientific Medicial Director of Genetics/Genomics Division at Sonora Quest Laboratories, Associate Professor of Pathology Department at University of Arizona
  • First experience with the Ion Torrent Genexus Workflow
    MAY 14, 2020 5:40 PM EDT
    First experience with the Ion Torrent Genexus Workflow
    Kojo Elenitoba-Johnson, MD
    Director, Center for Personalized Diagnostics Director, Division of Precision and Computational Diagnostics, University of Pennsylvania Perelman School of Medicine
  • Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
    MAY 14, 2020 5:00 PM EDT
    Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
    Xia Li, Ph.D., DABMGG, CG(ASCP), FACMG
    Scientific Medicial Director of Genetics/Genomics Division at Sonora Quest Laboratories, Associate Professor of Pathology Department at University of Arizona
  • Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
    MAY 14, 2020 4:40 PM CEST
    Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
    Marianne Grantham
    Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
  • Advantages and Challenges of Broad Molecular Profiling
    MAY 14, 2020 4:15 PM CEST
    Advantages and Challenges of Broad Molecular Profiling
    Ilaria Alborelli, PhD
    Scientific Operations Manager, Molecular Assay Development Unit Institute of Medical Genetics and Pathology, University Hospital of Basel - Switzerland
  • Genexus - A Major Step Forward in Diagnostic NGS
    MAY 14, 2020 3:30 PM CEST
    Genexus - A Major Step Forward in Diagnostic NGS
    Michael Hummel, PhD
    Head of Molecular Pathology, Charité - Universitätsmedizin Berlin, Institute of Pathology, Germany
  • Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
    MAY 14, 2020 3:00 PM CEST
    Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
    Nicola Normanno, MD
    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
  • Emerging Biomarkers in Non-small Cell Lung Cancer
    MAY 14, 2020 3:00 PM CEST
    Emerging Biomarkers in Non-small Cell Lung Cancer
    Luca Quagliata, PhD
    Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
  • Oncomine Precision Assay on Ion Torrent Genexus System for liquid biopsy sample
    MAY 14, 2020 2:40 PM SGT
    Oncomine Precision Assay on Ion Torrent Genexus System for liquid biopsy sample
    Siew-Kee (Amanda) Low, PhD
    Group Leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR)
  • First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
    MAY 14, 2020 2:15 PM SGT
    First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
    Philip Jermann, PhD
    Director of the Molecular Assay Development Unit, Institute of Pathology and Medical Genetics of Basel
  • NATA Accreditation of Next Generation Sequencing for CDx Testing
    MAY 14, 2020 1:25 PM SGT
    NATA Accreditation of Next Generation Sequencing for CDx Testing
    Luke Hesson, PhD, FFScRCPA
    Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
  • Test Validation in Medical Laboratories: the Australian Perspective
    MAY 14, 2020 1:25 PM SGT
    Test Validation in Medical Laboratories: the Australian Perspective
    Luke Hesson, PhD, FFScRCPA
    Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
  • Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
    MAY 14, 2020 1:00 PM SGT
    Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
    Dr. Pathmanathan Rajadurai, MBBS, FRCPA, FRCPath
    Senior Consultant Pathologist and Laboratory Director
  • Asia Pacific Session 1
    • Part 1: General education in precision oncology
    • A clinical-research-industry collaboration to bring blood genomics to cancer patients in New Zealand
      APR 29, 2021 12:05 PM +08
      A clinical-research-industry collaboration to bring blood genomics to cancer patients in New Zealand
      Cristin Gregor Print, PhD
      Professor, University of Auckland
    • Part 2: Driving NGS IVD future
    • Current and upcoming pharma collaboration and IVD strategy
      APR 29, 2021 12:25 PM +08
      Current and upcoming pharma collaboration and IVD strategy
      Garret Hampton
      President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
    • Part 2: Experiences with Oncomine Solutions for clinical research Part 2
    • Comprehensive Genomic Profiling, an Asia Pacific Perspective - AsPION Project
      APR 29, 2021 1:15 PM +08
      Comprehensive Genomic Profiling, an Asia Pacific Perspective - AsPION Project
      Dr. Tony Lim
      Senior Consultant
    • Part 2: Experiences with Oncomine Solutions for clinical research Part 2
    • Validation of combined DNA and RNA sequencing in Myeloid neoplasms
      APR 29, 2021 1:35 PM +08
      Validation of combined DNA and RNA sequencing in Myeloid neoplasms
      Neeraj Arora, MD, PDF
      Unipath Specialty Laboratory
  • Europe/North America Live Session 2
    • PART 1 EXPERIENCES WITH ONCOMINE SOLUTIONS FOR CLINICAL RESEARCH PART 1
    • Molecular pathology clinical and research activities in the COVID-19 era
      APR 29, 2021 3:05 PM CEST
      Molecular pathology clinical and research activities in the COVID-19 era
      Nicola Normanno, MD
      Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
    • PART 1 EXPERIENCES WITH ONCOMINE SOLUTIONS FOR CLINICAL RESEARCH PART 1
    • NSCLC molecular profiling: An NGS based approach using Oncomine Solutions
      APR 29, 2021 3:25 PM CEST
      NSCLC molecular profiling: An NGS based approach using Oncomine Solutions
      Artur Kowalik, Ph.D.
      Head of Department of Molecular Diagnostics, Holycross Cancer Center
    • Part 2: Experiences with Oncomine Solutions for clinical research Part 2
    • Comprehensive Genomic Profiling for Homologous Recombination Repair Deficiency (HRD) Assessment
      APR 29, 2021 4:15 PM CEST
      Comprehensive Genomic Profiling for Homologous Recombination Repair Deficiency (HRD) Assessment
      Dr. Andreas Jung
      Professor of Molecular Pathology, University of Munich
    • Part 2: Experiences with Oncomine Solutions for clinical research Part 2
    • Haematological malignancy samples molecular characterization - in a NGS way
      APR 29, 2021 4:35 PM CEST
      Haematological malignancy samples molecular characterization - in a NGS way
      Lihui Wang, Ph.D.
      Senior Clinical Scientist, Department of Haematology, Royal Liverpool University Hospital
  • America's Live Session 3
    • Part 1: General education in precision oncology
    • Point of care NGS in community practice
      APR 29, 2021 12:05 PM PDT
      Point of care NGS in community practice
      Brandon Sheffield, MD, FRCPC
      Physician Lead of Research, Medical Director of Immunohistochemistry and Molecular Pathology, Department of Pathology, William Osler Health System
    • Part 2: Driving NGS IVD future
    • Current and upcoming pharma collaboration and IVD strategy
      APR 29, 2021 12:25 PM PDT
      Current and upcoming pharma collaboration and IVD strategy
      Garret Hampton
      President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
    • Part 3: Experiences with Oncomine solutions for clinical research
    • Oncomine Reporter: A Powerful Tool for Oncology NGS Reports
      APR 29, 2021 1:15 PM PDT
      Oncomine Reporter: A Powerful Tool for Oncology NGS Reports
      Xia Li, Ph.D., DABMGG, CG(ASCP), FACMG
      Scientific Medicial Director of Genetics/Genomics Division at Sonora Quest Laboratories, Associate Professor of Pathology Department at University of Arizona
    • Experience with the Oncomine Precision Assay on Genexus System
      APR 29, 2021 1:35 PM PDT
      Experience with the Oncomine Precision Assay on Genexus System
      Leomar Ballester, MD, PhD
      Assistant Professor, Molecular Genetic Pathology and Neuropathology, Co-Director, Molecular Diagnostics Laboratory, University of Texas Health​ Science Center at Houston
Speakers

  • Neeraj Arora, MD, PDF
    Unipath Specialty Laboratory
    Biography

      I joined Tata Medical centre, Kolkata in 2013 and work in the service diagnostic laboratory as a consultant pathologist, taking care of the rotuine haematopathology, lymphoma pathology,  flow cytometry and Molecular genetics.  I along with my team have been involved in developing and implementing flowcytometry based minimal residual disease assays for haematological diseases like ALL and multiple myeloma. I have stong interest in lymphoma pathology and report the lymph nodes/bone marrow aspirates/biopsies.

      Under the guidance and vision of Dr Mammen Chandy (Director TMC) I have had the opportunity of successfully setting up affordable diagnostic molecular solutions for haematological and solid tumours using the latest techniques like NGS, digital PCR. Over the last 4-5 years we have successfully established and implemented molecular driven (Ion torrent based tissue genotyping for EGFR; digital PCR based T790M assays, cfDNA based EGFR genotyping, Oncomine comprehensve myeloid assays), standard treatment of care for our patients.

      I am involved in running and teaching fellows from the fellowship courses in haematopathology and molecular pathology.

    • Leomar Ballester, MD, PhD
      Assistant Professor, Molecular Genetic Pathology and Neuropathology, Co-Director, Molecular Diagnostics Laboratory, University of Texas Health​ Science Center at Houston
      Biography

        Dr. Ballester completed a B.S. in Biological Sciences at the University of Puerto Rico-Mayaguez, an M.D. degree at the UPR School of Medicine and a Ph.D. in pharmacology and genetics in the Department of Pharmacology at Vanderbilt University. Dr. Ballester joined the National Cancer Institute for Residency training in Anatomic Pathology (where he also served as chief resident). This was followed by fellowships in Molecular Genetic Pathology at Baylor College of Medicine and Neuropathology at the Houston Methodist/MDAnderson program. He is board certified by the American Board of Pathology in Anatomic Pathology, Neuropathology, and Molecular Genetic Pathology. Currently (since July 2017), Dr. Ballester has been an Assistant Professor in the Department of Pathology and Laboratory Medicine and the Department of Neurosurgery at the University of Texas Health Science Center in Houston. In addition to practicing clinical neuropathology, he serves as co-director of the Molecular Diagnostics Laboratory. He is also the principal investigator of an NIH-funded research program focusing on brain tumor biomarkers and minimally invasive diagnostic assays.

      • Cristin Gregor Print, PhD
        Professor, University of Auckland
        Biography

          Cris graduated in Medicine and Surgery from the University of Auckland in 1989 and began research while working as a house surgeon in Dunedin, NZ. A PhD in the University of Auckland led to a four-year postdoctoral fellowship in the Walter and Eliza Hall Institute in Melbourne, Australia before six years in Cambridge University, UK, where he was a Fellow of St Edmunds College and developed a deep interest in genomics and bioinformatics. While there he co-founded a bioinformatics company that became listed on the Tokyo stock exchange in 2007. In 2005 he returned to the University of Auckland where he leads a cross-disciplinary research team of clinicians, cell biologists and data scientists who use genomics, systems biology and bioinformatics to better understand human disease, especially cancer. He leads the Genomics Into Medicine Strategic Research Initiative in Auckland and Chairs the Auckland Regional Tissue Bank Scientific Advisory Board. He is a Deputy Chair of the NZ Institute of Environmental Science and Research (ESR) and a Principle Investigator in the Maurice Wilkins Centre. Previously, he served as President of the NZ Society for Oncology and was Director of the Bioinformatics Institute at the University of Auckland.

        • Garret Hampton
          President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
          Biography

            Garret Hampton, PhD., is currently President, Clinical Sequencing and Oncology at ThermoFisher Scientific, responsible for leading the company’s clinical next generation sequencing strategy. Prior to joining Thermo Fisher Scientific, Garret was Senior Vice President, Clinical Genomics, at Illumina, responsible for the development of sequencing-based solutions in oncology, reproductive health and whole genome sequencing for the diagnosis of rare disease. Before joining Illumina, Garret held a variety of leadership positions at Genentech / Roche, Celgene, and The Genomics Institute of the Novartis Research Foundation, focused on drug target discovery, drug development and precision medicine. Prior to moving into industry, Garret was Assistant Professor of Medicine at UCSD, San Diego after a 2-year postdoctoral fellowship at the Salk Institute for Biological Studies. He received his PhD from the Imperial Cancer Research Fund (now Cancer Research UK) under Sir Walter Bodmer. He has authored over 150 peer reviewed articles and reviews, with 10,000 lifetime citations.

          • Andrew Hutchison
            Associate Director, Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
          • Dr. Andreas Jung
            Professor of Molecular Pathology, University of Munich
            Biography

              Andreas Jung is a Professor for experimental pathology specialising in tumor biology (immunebiology – T-cell activation), mathematics and molecular pathology. He is heading the unit Molecular Pathology of the Institute for Pathology of the University of Munich (LMU, Ludwig-Maximilians University)and research group on tumormorphogenesis concentrating on role and regulation of epithelio-mesenchymal transition (EMT) in colorectal cancer, testing of activity of mutations and resistance mutations in Ba/F3 modell, inhibitory role of approved and studies targeted ALK-inhibitors on EML4-ALK fusions (different variants) and effect of alpelisib on seldom PIK3CA-mutations He is a member of CCCM (comprehensive cancer cancer Munich), BZKF (Bavarian Centre for Cancer Research), DKG (German Cancer Society), AEK (working group experimental cancer research in the DKG), DKFZ (German Cancer Research centre), DKTK (German Cancer consortium), NGM (national network genomic medicine lung cancer).

            • Artur Kowalik, Ph.D.
              Head of Department of Molecular Diagnostics, Holycross Cancer Center
              Biography

                Artur Kowalik, PhD, is a specialist in medical laboratory genetics. He is Head of the Department of Molecular Diagnostics at the Holycross Cancer Centre in Kielce. He also works at the Department of Medical Biology, Institute of Biology, Jan Kochanowski University in Kielce. The Department of Molecular Diagnostics performs molecular diagnostic tests for the patients treated in the Holycross Cancer Center in Kielce and many other centers in Poland. The group of tests performed includes stratification of patients with solid tumors for treatment with targeted therapies, detection of hereditary predisposition to cancer and diagnostics and monitoring of treatment effectiveness in hemato-oncology. The Department was the first in Poland to perform BRCA1/2 gene analysis for genetic counseling, using the NGS method. His research interests include cancer biology using modern molecular biology methods such as NGS and the application of liquid biopsy for cancer classification and monitoring of cancer treatment effectiveness.

              • Xia Li, Ph.D., DABMGG, CG(ASCP), FACMG
                Scientific Medicial Director of Genetics/Genomics Division at Sonora Quest Laboratories, Associate Professor of Pathology Department at University of Arizona
                Biography

                  Dr. Xia Li is the Scientific Medical Director of Genetics/Genomics Division at Sonora Quest Laboratories and Associate Professor of Pathology Department at University of Arizona. She oversees the operation of the laboratory and participates in the teaching and training of medical students and residents. Dr. Li has been working in the field of Genetics/Genomics diagnostics since 2008, and was certified in both Molecular and Cytogenetics through ABMGG. Before joining Sonora Quest Laboratories in 2016, Dr. Li was the Associate Director of Cytogenetics Laboratory at Cincinnati Children's Hospital from 2013 to 2016, and Associate Director of Cytogenetics Laboratory at AmeriPath Northeast from 2010 to 2013. She has extensive experience in cancer diagnostics using karyotyping, FISH, PCR, microarray and NGS technologies. She has published over 50 peer-reviewed articles and owns 2 patents. In her spare time, Dr. Li enjoys dancing, cooking, sewing, and hiking.

                • Dr. Tony Lim
                  Senior Consultant
                  Biography

                    Dr Tony Lim graduated with MBBS from National University of Singapore in 1998. He later then joined the Department of Pathology in Singapore General Hospital and finished his training in 2006, obtaining both FRCPath and FRCPA fellowships. After his HMDP in Liver and Gastrointestinal pathology at Mt Sinai Hospital in New York in 2008, he has returned to practice General Surgical pathology with special interest in Liver and Gastrointestinal Pathology, biliary tract diseases like pancreatobilary cancers and lung cancer. In the years of clinical research setting, he has been involved in numerous clinical trials with pharmaceutical companies and has authored and co-authored numerous publications. Currently, he is the Clinical Director of Personalized OMIC Lattice for Advanced Research and Improving Stratification (POLARIS)@Sing Health, a Sing Health Research Core Platform which utilizes Next Generation Sequencing (NGS) technology to conduct tests and aims to translate novel scientific discoveries into clinically validated assays.

                  • Nicola Normanno, MD
                    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
                    Biography

                      Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.

                    • Uma Ramasubramanian
                      Product Manager, Clinical Sequencing Division, Thermo Fisher Scientific
                    • Brandon Sheffield, MD, FRCPC
                      Physician Lead of Research, Medical Director of Immunohistochemistry and Molecular Pathology, Department of Pathology, William Osler Health System
                      Biography

                        Dr. Brandon Sheffield is an anatomic and molecular pathologist with the William Osler Health System. He is currently serving as the Medical Director of Immunohistochemistry and Molecular Pathology, and the Physician Lead of research for William Osler Health System. His professional focus is on the delivery of biomarkers to support precision oncology care in a community practice setting.

                      • Lihui Wang, Ph.D.
                        Senior Clinical Scientist, Department of Haematology, Royal Liverpool University Hospital
                        Biography

                          Dr. Lihui Wang obtained her quantification in Medicine in Peking University, China and her PhD degree in the University of Liverpool. She has been active in research on a variety of haematological malignancies in China, France, Scotland and England. Dr. Wang has been a Senior Clinical Scientist in Department of Haematology, Royal Liverpool University Hospital since year 2000. She has integrated both research project and NHS service to improve the molecular diagnosis, prognosis and monitoring for patients with haematological malignancies. Her research was mainly in investigating the role of BCR-ABL1 gene transcript monitoring in CML (Chronic Myeloid Leukaemia) patients under various clinical settings, the mechanism of tyrosine kinase inhibitor resistance in CML and the molecular mechanism of CML blast crisis (BC) transformation.

                          Dr. Wang has been involved in establishing and standardising BCR-ABL1 gene transcript monitoring in Liverpool, UK and across the world (WHO standard). Her role in NHS service was to establish and supervise molecular diagnostic and molecular monitoring service for patients with chronic myeloid leukaemia (CML), acute leukaemia and myeloproliferative neoplasms (MPN). Since 2018, Dr. Wang has been the Lead Scientist for Molecular Diagnostics, Haemato-oncology Diagnostic Service (HODS) in Royal Liverpool University Hospital. Her role was to establish and supervise the Haemato-oncology molecular diagnostic service for the region of Merseyside and Cheshire. Since 2019, Dr. Wang has been the Lead Scientist for NHS England Northwest Liverpool LCL Genomic Laboratory Hub (GLH).

                        C.E. Credits

                        The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                        Help

                        General Labroots Questions

                        email support@labroots.com  

                        Virtual Events and Webinars

                        Supported Configurations

                        • Operating System Internet Explorer Firefox Chrome Safari
                          Vista IE8+ FF10+ Chrome15+
                          Windows 7 IE8+ FF10+ Chrome15+
                          Windows 8 IE10 FF10+ Chrome15+
                          Mac OS X   FF10+ Chrome15+ Safari5.1+
                        • Cookie settings: session cookies enabled
                        • Browser configuration must have JavaScript enabled
                        • Adobe Flash player 10.2 or later

                        To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                        Internet Connection

                        • A minimum of 100Kbps is recommended for audio-only events
                        • A minimum of 300Kbps is recommended for speaker on-video events

                        Computer Equipment

                        • Screen Resolution: Minimum 1024x768
                        • Video Card: 65,000 colors minimum
                        • Sound card and speakers (or headphones) for hearing webcast in full format
                        • Audio Card: 16-bit minimum
                        • RAM: 512MB of free RAM

                        Firewall Protocol

                        • HTTP on port 80 or HTTPS on port 443
                        • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                        • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                        Work-At-Home Attendees

                        • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                        For A Seamless Experience

                        When using a mobile device, FREE Mobile Apps are available:

                        - For viewing Webinars:

                        - For viewing Virtual Events

                        Attendee Guide

                        • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                        Virtual Event and Webinar Support:

                        Continuing Education (CME/CE) Support

                        Demographics

                        Specialty

                        Molecular Diagnostics

                        Cancer

                        Molecular Biology

                        Molecular Genetics

                        Cancer Research

                        Genetics

                        Oncology

                        Research And Development

                        Genomics

                        Cancer Diagnostics

                        Research

                        Gene

                        Personalized Medicine

                        Human Genetics

                        Dna Sequencing

                        Geography

                        North America31%

                        Asia29%

                        Europe24%

                        Africa5%

                        South America4%

                        Oceania3%

                        Registration Source

                        Website Visitors89%

                        Labroots Registration (Also interested in)8%

                        Social Media Promotions1%

                        Email Promotions1%

                        Job Title

                        Facility/Department Manager11%

                        Executive11%

                        Research Scientist10%

                        Student9%

                        Educator/Faculty8%

                        Medical Doctor/Specialist8%

                        Scientist7%

                        Medical Laboratory Technician6%

                        Lab Management6%

                        Clinical Laboratory Scientist5%

                        Marketing/Sales5%

                        Pathologist4%

                        Biologist4%

                        Consultant3%

                        Post Doc2%

                        Other2%

                        Organization

                        Academic Institution22%

                        Hospital15%

                        Biotech Company10%

                        Clinical Laboratory9%

                        Life Science Company6%

                        Research Institute4%

                        Diagnostic Company3%

                        Government3%

                        Distribution/sales3%

                        Pharmaceutical Company2%

                        Consultant2%

                        Government/public2%

                        Medical Center1%

                        Medical School1%

                        Other4%

                        Loading Comments...
                        Show Resources
                        Attendees
                        • See more